State of Wisconsin Investment Board bought a new position in Aduro Biotech, Inc. (NASDAQ:ADRO) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 31,000 shares of the biotechnology company’s stock, valued at approximately $353,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Parametric Portfolio Associates LLC boosted its holdings in shares of Aduro Biotech by 15.9% in the 1st quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 2,119 shares in the last quarter. Tudor Investment Corp ET AL boosted its holdings in shares of Aduro Biotech by 34.8% in the 1st quarter. Tudor Investment Corp ET AL now owns 15,436 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 3,984 shares in the last quarter. American International Group Inc. boosted its holdings in shares of Aduro Biotech by 7.1% in the 1st quarter. American International Group Inc. now owns 21,840 shares of the biotechnology company’s stock worth $235,000 after acquiring an additional 1,447 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Aduro Biotech in the 2nd quarter worth approximately $408,000. Finally, Piermont Capital Management Inc. acquired a new position in shares of Aduro Biotech in the 1st quarter worth approximately $386,000. 35.05% of the stock is currently owned by institutional investors and hedge funds.

Several brokerages have recently commented on ADRO. BidaskClub downgraded Aduro Biotech from a “hold” rating to a “sell” rating in a report on Tuesday, August 8th. Canaccord Genuity set a $30.00 price objective on shares of Aduro Biotech and gave the stock a “buy” rating in a research report on Thursday, August 3rd. HC Wainwright set a $18.00 price objective on shares of Aduro Biotech and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Zacks Investment Research cut shares of Aduro Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Finally, Cowen and Company started coverage on shares of Aduro Biotech in a research report on Tuesday, July 18th. They issued an “outperform” rating for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $19.00.

In other Aduro Biotech news, VP Blaine Templeman sold 3,557 shares of the firm’s stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $10.99, for a total value of $39,091.43. Following the sale, the vice president now owns 65,275 shares in the company, valued at $717,372.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Stephen T. Isaacs sold 40,000 shares of the firm’s stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $10.50, for a total transaction of $420,000.00. Following the completion of the sale, the insider now owns 125,486 shares in the company, valued at approximately $1,317,603. The disclosure for this sale can be found here. Insiders sold 467,261 shares of company stock worth $5,359,431 in the last 90 days. Company insiders own 6.60% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/15/state-of-wisconsin-investment-board-buys-shares-of-31000-aduro-biotech-inc-adro.html.

Aduro Biotech, Inc. (ADRO) opened at 11.15 on Friday. The company’s market cap is $831.92 million. The company has a 50-day moving average of $11.67 and a 200 day moving average of $10.97. Aduro Biotech, Inc. has a 52-week low of $8.75 and a 52-week high of $15.52.

Aduro Biotech (NASDAQ:ADRO) last issued its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.02). Aduro Biotech had a negative net margin of 609.58% and a negative return on equity of 43.92%. The company had revenue of $5.90 million during the quarter, compared to analyst estimates of $3.98 million. During the same quarter in the prior year, the business earned $0.03 EPS. The business’s quarterly revenue was down 84.9% on a year-over-year basis. Equities research analysts predict that Aduro Biotech, Inc. will post ($1.37) EPS for the current year.

Aduro Biotech Company Profile

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Institutional Ownership by Quarter for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.